Related references
Note: Only part of the references are listed.The Akt/Mcl-1 pathway plays a prominent role in mediating antiapoptotic signals downstream of the B-cell receptor in chronic lymphocytic leukemia B cells
Pablo G. Longo et al.
BLOOD (2008)
Proteasome-dependent autoregulation of Bruton tyrosine kinase (Btk) promoter via NF-κB
Liang Yu et al.
BLOOD (2008)
Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation
Andrew E. Schade et al.
BLOOD (2008)
Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib, reveal novel kinase and nonkinase targets
Uwe Rix et al.
BLOOD (2007)
Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors
Marcus Bantscheff et al.
NATURE BIOTECHNOLOGY (2007)
CD154 induces a switch in pro-survival Bcl-2 family members in chronic lymphocytic leukaemia
Shaun Willimott et al.
BRITISH JOURNAL OF HAEMATOLOGY (2007)
The Btk tyrosine kinase is a major target of the Bcr-Abi inhibitor dasatinib
Oliver Hantschel et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Translational repression of MCL-1 couples stress-induced eIF2α phosphorylation to mitochondrial apoptosis initiation
Ralph M. Fritsch et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Noxa up-regulation and Mcl-1 cleavage are associated to apoptosis induction by bortezomib in multiple myeloma
Patricia Gomez-Bougie et al.
CANCER RESEARCH (2007)
MEK1/2 inhibitors sensitize Bcr/Abl+ human leukemia cells to the dual Abl/Src inhibitor BMS-354/825
Tri K. Nguyen et al.
BLOOD (2007)
The proteasome inhibitor bortezomib acts independently of p53 and induces cell death via apoptosis and mitotic catastrophe in B-cell lymphoma cell lines
Sandra J. Strauss et al.
CANCER RESEARCH (2007)
Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: Results from the US Intergroup Phase III Trial E2997
Michael R. Grever et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Differential Noxa/Mcl-1 balance in peripheral versus lymph node chronic lymphocytic leukemia cells correlates with survival capacity
Laura A. Smit et al.
BLOOD (2007)
Regulation of the proapoptotic BH3-only protein BIM by glucocorticoids, survival signals and proteasome in chronic lymphocytic leukemia cells
D. Iglesias-Serret et al.
LEUKEMIA (2007)
Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737
Victoria Del Gaizo Moore et al.
JOURNAL OF CLINICAL INVESTIGATION (2007)
CD154 induces p73 to overcome the resistance to apoptosis of chronic lymphocytic leukemia cells lacking functional p53
Frank Dicker et al.
BLOOD (2006)
The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized
Mark F. van Delft et al.
CANCER CELL (2006)
Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia
Marina Konopleva et al.
CANCER CELL (2006)
c-Abl expression in chronic lymphocytic leukemia cells: Clinical and therapeutic implications
Ke Lin et al.
CANCER RESEARCH (2006)
Glycogen synthase kinase-3 regulates mitochondrial outer membrane permeabilization and apoptosis by destabilization of MCL-1
U Maurer et al.
MOLECULAR CELL (2006)
Notch and NOXA-related pathways in melanoma cells
BJ Nickoloff et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY SYMPOSIUM PROCEEDINGS (2005)
Apoptosis induced by the kinase inhibitor BAY 43-9006 in human leukemia cells involves down-regulation of Mcl-1 through inhibition of translation
M Rahmani et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Low-level expression of proapoptotic Bcl-2-interacting mediator in leukemic cells in patients with chronic myeloid leukemia: Role of BCR/ABL, characterization of underlying signaling pathways, and reexpression by novel pharmacologic compounds
KJ Aichberger et al.
CANCER RESEARCH (2005)
Proteasome inhibitors trigger NOXA-mediated apoptosis in melanoma and myeloma cells
JZ Qin et al.
CANCER RESEARCH (2005)
Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia
MJ Keating et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML):: evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides
KJ Aichberger et al.
BLOOD (2005)
In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells
BT Messmer et al.
JOURNAL OF CLINICAL INVESTIGATION (2005)
Chronic lymphocytic leukemia cells display p53-dependent drug-induced Puma upregulation
WJM Mackus et al.
LEUKEMIA (2005)
High expression of bfl-1 contributes to the apoptosis resistant phenotype in B-cell chronic lymphocytic leukemia
AA Morales et al.
INTERNATIONAL JOURNAL OF CANCER (2005)
Fludarabine treatment of patients with chronic lymphocytic leukemia induces a p53-dependent gene expression response
A Rosenwald et al.
BLOOD (2004)
Microenvironmental interactions and survival of CLL B-cells
IM Pedersen et al.
LEUKEMIA & LYMPHOMA (2004)
Roles of Bim in apoptosis of normal and Bcr-Abl-expressing hematopoietic progenitors
R Kuribara et al.
MOLECULAR AND CELLULAR BIOLOGY (2004)
CD40 stimulation of B-cell chronic lymphocytic leukaemia cells enhances the anti-apoptotic profile, but also Bid expression and cells remain susceptible to autologous cytotoxic T-lymphocyte attack
AP Kater et al.
BRITISH JOURNAL OF HAEMATOLOGY (2004)
Expression profiling via novel multiplex assay allows rapid assessment of gene regulation in defined signalling pathways
E Eldering et al.
NUCLEIC ACIDS RESEARCH (2003)
Phosphorylation of Bim-EL by Erk1/2 on serine 69 promotes its degradation via the proteasome pathway and regulates its proapoptotic function
F Luciano et al.
ONCOGENE (2003)
Activation of the ERK1/2 signaling pathway promotes phosphorylation and proteasome-dependent degradation of the BH3-only protein, Bim
R Ley et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Effects of the Bcr/abl kinase inhibitors STI571 and adaphostin (NSC 680410) on chronic myelogenous leukemia cells in vitro
BMF Mow et al.
BLOOD (2002)
Molecular cloning and characterization of six novel isoforms of human Bim, a member of the proapoptotic Bcl-2 family
MUT Miyashita et al.
FEBS LETTERS (2001)
p53 dysfunction in B-cell chronic lymphocytic leukemia:: inactivation of ATM as an alternative to TP53 mutation
AR Pettitt et al.
BLOOD (2001)
Blockade of the Bcr-Abl kinase activity induces apoptosis of chronic myelogenous leukemia cells by suppressing signal transducer and activator of transcription 5-dependent expression of Bcl-XL
M Horita et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2000)
Share Paper
